A recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of
Erica L Harris1, Vincent Roy2, Martin Montagne2
1Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Abstract:
Cyclin D2 (CCND2) stabilization underpins a range of macrocephaly-associated disorders through mutation of CCND2 or activating mutations in upstream genes encoding PI3K-AKT pathway components. Here, we describe three individuals with overlapping macrocephaly-associated phenotypes who carry the same recurrent de novo c.179G>A (p.Arg60Gln) variant in Myc-associated factor X (MAX). The mutation, located in the b-HLH-LZ domain, causes increased intracellular CCND2 through increased transcription but it does not cause stabilization of CCND2. We show that the purified b-HLH-LZ domain of MAXArg60Gln (Max∗Arg60Gln) binds its target E-box sequence with a lower apparent affinity. This leads to a more efficient heterodimerization with c-Myc resulting in an increase in transcriptional activity of c-Myc in individuals carrying this mutation. The recent development of Omomyc-CPP, a cell-penetrating b-HLH-LZ-domain c-Myc inhibitor, provides a possible therapeutic option for MAXArg60Gln individuals, and others carrying similar germline mutations resulting in dysregulated transcriptional c-Myc activity.
Insights
A novel Myc-associated factor X (MAX) gene variant causes macrocephaly by increasing cyclin D2 (CCND2) transcription. This MAX mutation enhances c-Myc activity, suggesting a therapeutic target for related disorders.
Area of Science:
- Genetics
- Molecular Biology
- Developmental Biology
Background:
- Macrocephaly disorders are often linked to Cyclin D2 (CCND2) stabilization.
- Mutations in CCND2 or the PI3K-AKT pathway are common causes.
Purpose of the Study:
- Investigate the genetic basis of macrocephaly in three individuals with overlapping phenotypes.
- Characterize a novel de novo variant in the Myc-associated factor X (MAX) gene.
Main Methods:
- Genetic sequencing to identify variants.
- In vitro analysis of the MAX b-HLH-LZ domain protein function.
- Assessment of c-Myc transcriptional activity.
Main Results:
- Identified a recurrent de novo c.179G>A (p.Arg60Gln) variant in MAX in three individuals.
- The MAX Arg60Gln mutation increases CCND2 transcription but not its stabilization.
- The MAX Arg60Gln variant exhibits reduced binding affinity, enhancing c-Myc heterodimerization and transcriptional activity.
Conclusions:
- The MAX Arg60Gln variant contributes to macrocephaly through increased c-Myc-driven transcription.
- Omomyc-CPP, a c-Myc inhibitor, presents a potential therapeutic strategy for individuals with this MAX mutation.
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Pleiotropy
Cancers Originate from Somatic Mutations in a Single Cell
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...


